June 1970

Hypoerythropoietinemia and Anemia

Author Affiliations


From the Department of Internal Medicine, University of Texas Southwestern Medical School, and the Radioisotope Laboratory, Veterans Administration Hospital, Dallas. Dr. Douglass is now at the Clinic of the Southwest, Houston.

Arch Intern Med. 1970;125(6):1050-1055. doi:10.1001/archinte.1970.00310060128017

Aprime aspect of the anemia associated with renal disease is the evidence of a hypoproliferative state, in essence an erythron which appears to lack erythropoietic stimulus. That the erythropoietic stimulus is a humoral material (erythropoietin) with its origin or activation in the kidney was first demonstrated by Jacobson and co-workers in 1957.1,2 Recent reviews by Gordon et al,3 Adamson et al,4 and Stohlman 5 have documented the extensive investigative data clarifying the important role of the kidney in man as a primary site of erythropoietin production and its resultant action in the regulation of red blood (RBC) production. Although extrarenal erythropoietic stimulatory potential appears to exist in man,6-11 the renal source or renal activation of erythropoietin is the presumed physiologically significant mechanism in the normal modulation of erythropoiesis. Characteristic of the nonstimulated or hypoproliferative anemia of renal disease is that the degree of the anemia is

First Page Preview View Large
First page PDF preview
First page PDF preview